Pharmaceutical policies for gaining access to high-priced medicines: a comparative analysis between England and Brazil

Detalhes bibliográficos
Autor(a) principal: Vicente,Geison
Data de Publicação: 2022
Outros Autores: Calnan,Michael, Rech,Norberto, Leite,Silvana
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Saude em Debate
Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0103-11042022000300886
Resumo: ABSTRACT Although the National Health Service (NHS) and the Unified Health System (SUS) are systems with similar universal principles, they can show different political measure patterns in the pharmaceutical field. This paper aimed to provide a comparative analysis of pharmaceutical policies highlighting strategies to guarantee access and sustainability to High-Price Medicines (HPMs) in Brazil and England. We performed an integrative literature review in electronic databases, supplemented by grey literature searched on governmental platforms (laws, decrees, ordinances, and resolutions). A total of Forty-seven articles and seven policies were selected and categorized for analysis. The results showed that both countries apply distinct policies to ensure access to HPMs, among them, policies to define price and reimbursement and actions to regulate the use inside the system. Also, these countries apply distinct policies to their sustainability as local partnerships for product development in Brazil and confidential managed agreements with multinational industries in the England. In conclusion, despite similarities in principles, these countries have been proposing and applying distinct pharmaceutical policies to maintain access and ensure the sustainability of their health systems.
id CBES-1_1638414ba8eadc1eb5eff8ee9fc00d80
oai_identifier_str oai:scielo:S0103-11042022000300886
network_acronym_str CBES-1
network_name_str Saude em Debate
repository_id_str
spelling Pharmaceutical policies for gaining access to high-priced medicines: a comparative analysis between England and BrazilHealth policyTechnologyHigh-CostPublic healthABSTRACT Although the National Health Service (NHS) and the Unified Health System (SUS) are systems with similar universal principles, they can show different political measure patterns in the pharmaceutical field. This paper aimed to provide a comparative analysis of pharmaceutical policies highlighting strategies to guarantee access and sustainability to High-Price Medicines (HPMs) in Brazil and England. We performed an integrative literature review in electronic databases, supplemented by grey literature searched on governmental platforms (laws, decrees, ordinances, and resolutions). A total of Forty-seven articles and seven policies were selected and categorized for analysis. The results showed that both countries apply distinct policies to ensure access to HPMs, among them, policies to define price and reimbursement and actions to regulate the use inside the system. Also, these countries apply distinct policies to their sustainability as local partnerships for product development in Brazil and confidential managed agreements with multinational industries in the England. In conclusion, despite similarities in principles, these countries have been proposing and applying distinct pharmaceutical policies to maintain access and ensure the sustainability of their health systems.Centro Brasileiro de Estudos de Saúde2022-01-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0103-11042022000300886Saúde em Debate v.46 n.134 2022reponame:Saude em Debateinstname:Centro Brasileiro de Estudos de Saudeinstacron:CBES10.1590/0103-1104202213422info:eu-repo/semantics/openAccessVicente,GeisonCalnan,MichaelRech,NorbertoLeite,Silvanaeng2022-09-08T00:00:00Zoai:scielo:S0103-11042022000300886Revistahttp://www.scielo.br/scielo.php?script=sci_serial&pid=0103-1104&lng=en&nrm=isohttps://old.scielo.br/oai/scielo-oai.phprevista@saudeemdebate.org.br2358-28980103-1104opendoar:2022-09-08T00:00Saude em Debate - Centro Brasileiro de Estudos de Saudefalse
dc.title.none.fl_str_mv Pharmaceutical policies for gaining access to high-priced medicines: a comparative analysis between England and Brazil
title Pharmaceutical policies for gaining access to high-priced medicines: a comparative analysis between England and Brazil
spellingShingle Pharmaceutical policies for gaining access to high-priced medicines: a comparative analysis between England and Brazil
Vicente,Geison
Health policy
Technology
High-Cost
Public health
title_short Pharmaceutical policies for gaining access to high-priced medicines: a comparative analysis between England and Brazil
title_full Pharmaceutical policies for gaining access to high-priced medicines: a comparative analysis between England and Brazil
title_fullStr Pharmaceutical policies for gaining access to high-priced medicines: a comparative analysis between England and Brazil
title_full_unstemmed Pharmaceutical policies for gaining access to high-priced medicines: a comparative analysis between England and Brazil
title_sort Pharmaceutical policies for gaining access to high-priced medicines: a comparative analysis between England and Brazil
author Vicente,Geison
author_facet Vicente,Geison
Calnan,Michael
Rech,Norberto
Leite,Silvana
author_role author
author2 Calnan,Michael
Rech,Norberto
Leite,Silvana
author2_role author
author
author
dc.contributor.author.fl_str_mv Vicente,Geison
Calnan,Michael
Rech,Norberto
Leite,Silvana
dc.subject.por.fl_str_mv Health policy
Technology
High-Cost
Public health
topic Health policy
Technology
High-Cost
Public health
description ABSTRACT Although the National Health Service (NHS) and the Unified Health System (SUS) are systems with similar universal principles, they can show different political measure patterns in the pharmaceutical field. This paper aimed to provide a comparative analysis of pharmaceutical policies highlighting strategies to guarantee access and sustainability to High-Price Medicines (HPMs) in Brazil and England. We performed an integrative literature review in electronic databases, supplemented by grey literature searched on governmental platforms (laws, decrees, ordinances, and resolutions). A total of Forty-seven articles and seven policies were selected and categorized for analysis. The results showed that both countries apply distinct policies to ensure access to HPMs, among them, policies to define price and reimbursement and actions to regulate the use inside the system. Also, these countries apply distinct policies to their sustainability as local partnerships for product development in Brazil and confidential managed agreements with multinational industries in the England. In conclusion, despite similarities in principles, these countries have been proposing and applying distinct pharmaceutical policies to maintain access and ensure the sustainability of their health systems.
publishDate 2022
dc.date.none.fl_str_mv 2022-01-01
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0103-11042022000300886
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0103-11042022000300886
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 10.1590/0103-1104202213422
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv text/html
dc.publisher.none.fl_str_mv Centro Brasileiro de Estudos de Saúde
publisher.none.fl_str_mv Centro Brasileiro de Estudos de Saúde
dc.source.none.fl_str_mv Saúde em Debate v.46 n.134 2022
reponame:Saude em Debate
instname:Centro Brasileiro de Estudos de Saude
instacron:CBES
instname_str Centro Brasileiro de Estudos de Saude
instacron_str CBES
institution CBES
reponame_str Saude em Debate
collection Saude em Debate
repository.name.fl_str_mv Saude em Debate - Centro Brasileiro de Estudos de Saude
repository.mail.fl_str_mv revista@saudeemdebate.org.br
_version_ 1754209002153050112